Professional Documents
Culture Documents
Evidence
Ilse Truter
Drug Utilization Research Unit (DURU), Department of Pharmacy, Nelson Mandela Metropolitan University
A peptic ulcer is an erosion in a segment of the gastrointestinal mucosa, typically in the stomach (gastric ulcer) or
the first few centimeters of the duodenum (duodenal ulcer), that penetrates through the muscularis mucosae.1
Symptoms typically include burning epigastric pain that is often relieved by food.1
Nearly all ulcers are caused by Helicobacter pylori (H pylori) infection or non-steroidal anti-inflammatory drug
(NSAID) use. H pylori has been clearly associated with both gastric and duodenal ulcers, and, in the absence of
NSAIDs, eradication of the organism results in long-term healing with re-infection being rare.2 H pylori is said to
account for 80% of all gastric or stomach ulcers and more than 90% of all duodenal ulcers.3,4 Confirmation of the
presence of H pylori prior to eradication therapy is recommended.2
Ulcers can occur at any age, including infancy and childhood, but
are most common in middle-aged adults.1 Peptic ulcer (gastric
and duodenal) occurs most commonly in patients aged 30 to 50
years6, although patients over the age of 60 years account for
80% of deaths even though they only account for 15% of cases7.
Prevalence has shifted from predominance in males to similar
occurrences in both sexes.8 Lifetime prevalence is approximately
11% to 14% for men and 8% to 11% for women.8
Aetiology/pathophysiology
10
Helicobacter pylori infection: As already mentioned, H pylori is present in the mucosa of 80% of
patients with peptic ulceration and gastritis, while it is
only present in 20% of the normal healthy population.
Genetic tendency: A genetic tendency occurs
especially in the case of duodenal ulceration.
Furthermore, a family history exists in 50% to 60% of
children with duodenal ulcer.1
Medicine: Medicine such as aspirin, NSAIDs and
corticosteroids can cause peptic ulceration.
Alcohol: Chronic drinkers of alcohol develop
ulceration, while the occasional drinker normally
only develops gastritis. Although alcohol is identified
as a strong promoter of acid secretion, no definite
data link moderate amounts of alcohol to the development or delayed healing of ulcers.1
Cigarette smoking1: It is a risk factor for the development of ulcers and their complications. In addition, smoking impairs ulcer healing and increases
the incidence of recurrence. Risk correlates with the
number of cigarettes smoked per day.
Stress: Severe physiologic stress can cause peptic
ulcer disease, for example burns, central nervous
system trauma, surgery and severe medical illness.8
Bile salts and pancreatic enzymes: They can
cause ulceration when they leak back into the
stomach on account of an inefficient pyloric sphincter, or when stasis of the intestinal bolus occurs as a
result of partial obstruction.
Toxins secreted by micro-organisms: e.g. toxins
secreted in chronic gastroenteritis.
Hypersecretory states. This is an uncommon
cause. Examples include gastrinoma (ZollingerEllison syndrome), multiple endocrine neoplasia
(MEN-I), antral G cell hyperplasia, systemic mastocy-
Property
Pain:
Localisation
Gastritis
Epigastric
Gastric Ulcer
Duodenal
Ulcer
Epigastric
Epigastric or
umbilical
Spreading
Substernal
Substernal
Back
Nature
Burning
Sharp, stabbing Dull
Frequency
Especially after Every day
Periodic, somecausative fac- Pain more se- times persistent
tors, e.g. alcohol vere
Response to in- Pain similar or Seldom
Pain improves
gestion of food better
Night time pain Seldom
Relieves pain
Often
Antacids
Relieves pain
Relieves pain
Family history
Seldom
Occasionally
Age
Any age
Always
Population
Recommended
Should be considered
Not recommended
Often
Occasionally
11
Evidence
A thorough history regarding habits and medication usage should be taken, a physical examination can be performed and, if appropriate,
laboratory/diagnostic tests (often endoscopy) may be
conducted to exclude other conditions. The overall aim is to
reduce epigastric pain, to improve the patients quality of life
by identifying, treating and/or eliminating the underlying
cause of the peptic ulceration, and to use pharmacological
therapy when indicated. This should be accomplished
without adverse effects or with clinically acceptable adverse
effects. A list of aspects that should be addressed in a
patient assessment history is given in Table III.
If the pharmacist is convinced that a patient is only suffering
from gastritis, therapeutic treatment can be offered. If a
peptic ulcer is suspected, the pharmacist can provide
temporary, symptomatic treatment, followed by referral to a
medical practitioner. Empiric therapy is therefore often
begun without a definite diagnosis.
When to refer
12
Table III: Specific questions to ask the patient with suspected peptic ulcer diease
Aspect
Question
Evidence
Non-pharmacological management
Pharmacological treatment
14
Sucralfate
Sucralfate, a sucrose-hydrogen-sulphate-aluminum complex,
is a mucosal protective agent. It has a local protective action
on the ulcer base, without the side-effects that may occur
with systemic agents.2 In the stomach, a paste-like gel is
formed from a reaction with hydrochloric acid, which adheres
to the base of ulcer craters (both in the stomach and duodenum), protecting ulcer epithelium from ulcerogenic substances such as gastric acid, pepsin and bile.2 It also directly
adsorbs bile and pepsin. It has no effect on acid output or
gastrin secretion.
Bismuth subcitrate
Bismuth subcitrate has a high affinity for damaged tissue and
forms a visible coating in the base of the ulcer crater,
protecting the ulcer from gastric acid, pepsin and bile. Its
efficacy in the treatment of duodenal and gastric ulcers
compares favourably with H2-receptor antagonists and other
ulcer healing agents.2
Evidence-based guidelines
The efficacy of the various H pylori eradication regimens is
reviewed in the full National Institute for Health and Clinical
Excellence (NICE) guideline on dyspepsia.12,13 PRODIGY
recommendations for the first-line treatment of peptic ulcer
disease mirror those advised by NICE10 and will not be
discussed in detail. In Figure 1 the management flowchart
for gastric ulcer according to the NICE guidelines is given,
and in Figure 2 the management flowchart for duodenal
ulcer.
Table IV provides an overview of the NICE guidelines on
initial therapy for peptic ulcer disease. One week triple
therapy in a regimen containing clarithromycin is considered
to be the gold standard.4 PPI-based dual therapy has been
shown to be less effective than triple therapy, and regimens
containing a PPI, amoxicillin and metronidazole are less
effective than clarithromycin-based regimens.4
NICE guidelines12,13 recommend either of the following for
seven days as first line therapy:
PPI full dose twice daily, amoxicillin 1 g twice daily and
clarithromycin 500 mg twice daily; or
PPI full dose twice daily, metronidazole 400 mg twice
daily and clarithromycin 250 mg twice daily.
These regimens are equally effective and achieve eradication in 80% to 85% of patients.4,13 Although the second
regimen is less expensive than the first one, there are some
concerns that the second therapy may induce resistance to
both metronidazole and clarithromycin.4 Resistance to
amoxicillin is not as common.4
Increasing the length of therapy to 14 days increases
eradication rates by approximately 10% although it was not
found to be cost-effective when modeled by NICE.4,13 The
increased length of treatment is also likely to result in lower
adherence.
Table IV: NICE guidelines on initial therapy
for peptic ulcer disease4,13
Diagnosis
Treatment
Follow-up
15
Gastric ulcer
Stop NSAIDs,
if used 1
Full dose PPI for
two months
H pylori positive
Ulcer associated
with NSAID use
H pylori
positive
Eradication
therapy3
H pylori
negative
Endoscopy and
H pylori test4
H pylori positive
Ulcer not associated
with NSAID use
Test for
H pylori2
Ulcer healed
H pylori
negative
Healed
Endoscopy4
Not healed
Periodic review 6
1
2
3
4
5
6
16
Refer to specialist
secondary care
Refer to specialist
secondary care
If NSAID continuation is necessary, after ulcer healing offer long term gastric protection or consider substitution to a newer COXselective NSAID.
Use a carbon-13 urea breath test, stool antigen test or, when performance has been validated, laboratory-based serology.
Use a PPI, amoxicillin, clarithromycin 500 mg (PAC500) regimen or a PPI, metronidazole, clarithromycin 250 mg (PMC250) regimen.
Follow guidance found in the British National Formulary for selecting 2nd line therapies.
After two attempts at eradication manage as H pylori negative.
Perform endoscopy 6-8 weeks after treatment. If retesting for H pylori use a carbon-13 urea breath test.
Offer low dose treatment, possibly used on an as required basis, with a limited number of repeat prescriptions.
Review care annually to discuss symptoms, promote stepwise withdrawal of therapy when appropriate and provide lifestyle advice. In
some patients with an inadequate response to therapy it may become appropriate to refer to a specialist.
Duodenal ulcer
Stop NSAIDs,
if used1
Full dose PPI for
two months
Test positive
Ulcer associated
with NSAID use
Eradication
therapy 3
Test negative
Test positive
Ulcer not associated
with NSAID use
Response
Test for
H pylori2
No response
or relapse
Retest for
H pylori4
Negative
Response
No response
Positive
Eradication
therapy 5
No response
or relapse
2
3
4
5
6
7
No response
Exclude other
causes of DU7
Low dose
treatment as
required 6
Response
Response
Review 8
If NSAID continuation is necessary, after ulcer healing offer long term gastric protection or consider substitution to a newer COXselective NSAID.
Use a carbon-13 urea breath test, stool antigen test or, when performance has been validated, laboratory-based serology.
Use a PPI, amoxicillin, clarithromycin 500 mg (PAC500) regimen or a PPI, metronidazole, clarithromycin 250 mg (PMC250) regimen
Use a carbon-13 urea breath test.
Follow guidance found in the British National Formulary for selecting 2nd line therapies.
Offer low dose treatment, possibly used on an as required basis, with a limited number of repeat prescriptions.
Consider non-compliance with treatment, possible malignancy, failure to detect H pylori infection due to recent PPI or antibiotic
ingestion, inadequate testing, or simple misclassification; surreptitious or inadvertent NSAID or aspirin use; ulceration due to ingestion
of other drugs; Zollinger-Ellison syndrome; Crohns disease.
A small number of patients with chronic, refractory peptic ulceration may require maintenance acid suppression. In some patients with
an inadequate response to therapy it may become appropriate to refer to a specialist for a second opinion.
Review care annually to discuss symptoms, promote stepwise withdrawal of therapy when appropriate and provide lifestyle advice.
17
Evidence
18
example, ibuprofen 400 mg three times daily). For NSAIDassociated ulcers, NSAIDs should be stopped where
possible, and simple analgesics such as paracetamol with or
without a low dose opioid should be prescribed. Those with
inflammatory diseases, for example rheumatoid arthritis, may
however depend on NSAIDs for effective pain relief.
For prophylaxis, if a NSAID must be used, a concurrent
gastroprotectant should be used or one of the cyclo-oxygenase (COX)-2 selective agents can be considered. When
making this decision, the outcome needs to be considered
whether serious gastrointestinal bleeding can be prevented
and whether symptomatic ulcers can be prevented.
Misoprostol can be used for gastroprotection. A reduction in
serious events has not been demonstrated with PPIs, but
they do reduce the incidence of symptomatic ulcers.4 More
research is, however, needed. H2-antagonists should not be
used for gastroprotection.4 Standard doses have been
shown endoscopically to prevent duodenal ulcers but not
gastric ulcers, while double doses have been shown to
reduce the incidence of endoscopically detected ulcers but
not symptomatic ulcers or serious gastrointestinal complications. In theory, COX-2 inhibitors inhibit the production of
inflammatory prostaglandins while preserving production of
gastroprotective prostaglandins driven by COX-1.4 They can
be used in high risk patients without cardiovascular disease.8
The actual clinical benefit of these drugs has generated
much controversy and the reported increased incidence of
cardiac events fall outside the scope of this article. Therefore, on the basis of cost, safety and tolerability, the PPIs are
most commonly used for gastroprotection. Misoprostol can
also be used, provided the side effects are tolerable. COX-2
inhibitors are an option if the patient is not using aspirin.
For treatment, studies have shown that ulcer healing can be
achieved with PPIs in the continued presence of NSAIDs. The
OMNIUM study14 was a double-blind study, where 935 patients
who required continuous NSAID therapy and who had ulcers or
more than 10 erosions in the stomach or duodenum (or both)
were randomly assigned to receive 20 mg or 40 mg of
omeprazole orally in the morning or 200 g of misoprostol orally
four times daily. The overall rates of successful treatment of
ulcers, erosions, and symptoms associated with NSAIDs were
similar for the two doses of omeprazole and misoprostol.
Maintenance therapy with omeprazole was associated with a
lower rate of relapse than misoprostol. Omeprazole was better
tolerated than misoprostol.
In the ASTRONAUT study15, 541 patients who required
continuous treatment with NSAIDs and who had ulcers or
more than 10 erosions in either the stomach or duodenum
were studied. Patients were randomly assigned to doubleblind treatment with omeprazole, 20 mg or 40 mg orally per
day, or ranitidine, 150 mg orally twice a day, for four or eight
weeks. It was concluded that in patients who use NSAIDs
regularly, omeprazole healed and prevented ulcers more
effectively than did ranitidine.
Evidence
Other ulcers
The prevalence of H pylori is falling with successive birth
cohorts, so ulcers unrelated to H pylori are becoming a
proportionally greater problem.4 These ulcers should heal
with a four to eight week course of PPI, but other aspects
should also be considered, for example failure to detect H
pylori due to recent acid suppression or antibiotic use,
inadvertent NSAID use, other drugs (for example,
biphosphonates or sustained release potassium chloride),
and alternative diagnoses such as Zollinger-Ellison syndrome or Crohns disease.
9.
10.
11.
12.
13.
14.
15.
Conclusion
References:
1.
The Merck Manual of Diagnosis and Therapy. 2006. 18th Edition.
Edited by MH Beers. Whitehouse Station: Merck Research Laboratories.
2.
South African Medicines Formulary (SAMF), 8th Edition. 2008. Edited by
CJ Gibbon. Claremont: Health and Medical Publishing Group of the
South African Medical Association.
3.
Anderson J & Gonzalez J. 2000. H pylori Infection: Review of the
Guideline for Diagnosis and Treatment. Geriatrics, 55 (6): 44-49.
4.
Greer D. 2006. Peptic Ulcer Disease Pharmacological Treatment.
Hospital Pharmacist, 13: 245-250.
5.
Dekker A, Dreyer AC & Smit R. 1993. Pharmacist Initiated Therapy:
Recognition and Treatment of Minor Ailments. Kenwyn: Juta & Co, Ltd.
6.
Rutter P. 2005. Symptoms, Diagnosis and Treatment: A Guide for
Pharmacists and Nurses. Edinburgh: Elsevier Churchill Livingstone.
7.
Rutter P. 2004. Community Pharmacy: Symptoms, Diagnosis and
Treatment. Edinburgh: Churchill Livingstone.
8.
Le TH & Fantry GT. 2008. Peptic Ulcer Disease. eMedicine, 17 July.
Available on the web: http://www.emedicine.com/MED/topic1776.htm
(date accessed: 3 November 2008).
20
In collaboration with the Foundation for Professional Development and USAID/PEPFAR, the Medicines Information Centre in
Cape Town provides a toll-free national HIV hotline to all health
care workers in South Africa for patient treatment related
enquiries. The service is free to health care workers.
The toll-free national HIV health care worker hotline provides
information on queries relating to:
HIV testing
Post exposure prophylaxis: health care workers
and sexual assault victims
Management of HIV in pregnancy, and prevention of mother-to-child transmission
Antiretroviral therapy:
- When to initiate
- Treatment selection
- Recommendations for laboratory and clinical
monitoring
- How to interpret and respond to laboratory
results
- Management of adverse events
Drug interactions
Treatment and prophylaxis of opportunistic infections
Drug availability
Adherence support
The hotline operates from
Mondays to Fridays 8.30am - 4.30pm.
Toll-free number - 0800 212 506